ArticleEpigenomes2026
Genome-Wide DNA Methylation Profiling Reveals Stage- and Severity-Associated Epigenetic Alterations in Children with Posterior Urethral Valve-Associated Chronic Kidney Disease.
Article in Epigenomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) is an important cause of morbidity in children, particularly in those with congenital anomalies of the kidney and urinary tract. Although epigenetic alterations have been implicated in CKD, stage-associated genome-wide DNA methylation changes remain poorly characterized in posterior urethral valves (PUV). This study aimed to characterize DNA methylation patterns across CKD stages in children with PUV and identify potential methylation markers associated with CKD severity.
methodsGenome-wide DNA methylation profiling was performed on peripheral blood DNA from 20 boys with PUV stratified by CKD stage and 19 age-matched healthy male controls using the Illumina MethylationEPIC v2.0 array. Analyses included a global stage-wise model, stage-specific comparisons against controls and between CKD stages, an overall PUV-associated CKD-versus-control model, functional enrichment analysis, candidate CKD progression gene analysis, and CKD severity-associated methylation analysis.
resultsA global stage-wise analysis identified 11,134 CpG sites showing significant methylation variation across controls and PUV-associated CKD. Differential methylation burden was limited in early CKD stages but increased markedly in advanced CKD, with 4734 and 20,242 DMPs identified in Stage 4 and Stage 5, respectively. DMP-associated genes in advanced CKD stages showed enrichment of immune-related, structural remodeling, and intracellular signaling pathways. Candidate gene analysis identified significant methylation changes in previously reported CKD progression-associated genes, with greater representation in advanced CKD stages. CKD severity-associated analysis identified cg16879596_BC21, annotated to
conclusionsPUV-associated CKD is characterized by stage-associated DNA methylation changes, with a marked increase in methylation burden in advanced CKD stages. The findings highlight immune, structural remodeling, and signaling pathways associated with advanced CKD and identify
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.